Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC.
Michael L ChengChristie J LauMarina S D MilanJulianna G SuppleeJonathan W RiessPenelope A BradburyPasi A JänneGeoffrey R OxnardCloud P PaweletzPublished in: JCO precision oncology (2021)
Plasma ctDNA response is an early phenomenon, with the majority of change detectable within the first cycle of therapy. These kinetics may offer an opportunity for early insight into treatment effect before standard imaging timepoints.